OLR

Kibo and OLR Forge Strategic Partnership to Propel Retail Innovation and ROI with Advanced Composable Commerce

Retrieved on: 
Tuesday, March 26, 2024
API, Partnership, Implementation, IO, Commerce, OLR, Kibo, Online shopping

AUSTIN, Texas, March 26, 2024 /PRNewswire-PRWeb/ -- Kibo Commerce, a market leader in composable unified commerce solutions, has announced a strategic partnership with OLR, specialist systems integrator of Oracle Retail Solutions. The collaboration introduces the "Souk Store," an accelerator developed by OLR that expedites the migration of catalogues, content, customers, and site history. This accelerator is built on proven structures that drive conversion, offering an easy-to-navigate experience for users, comprehensive search engine optimization, and offers a seamless transition to Kibo's platform.

Key Points: 
  • Kibo Commerce partners with OLR to introduce the "Souk Store" accelerator, which streamlines migration processes and delivers a modern, seamless retail experience.
  • AUSTIN, Texas, March 26, 2024 /PRNewswire-PRWeb/ -- Kibo Commerce , a market leader in composable unified commerce solutions, has announced a strategic partnership with OLR , specialist systems integrator of Oracle Retail Solutions.
  • The collaboration introduces the "Souk Store," an accelerator developed by OLR that expedites the migration of catalogues, content, customers, and site history.
  • For more information about the partnership and how it can benefit your business, please visit: Kibo Composable Commerce Consultancy & Implementation — OLR

Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, HKEX, Rituximab, Lenalidomide, Toxicity, Treatment, Progression-free survival, Lymphoid leukemia, MCL, ASH, Aes, Refractory, Bleeding, Patient, Abstract, PFS, Impact, TLS, POLARIS, MRD, DOR, Pharmacokinetics, OLR, Atrial fibrillation, Medicine, SSE, ORR, Diarrhea, Cancer, Peking Union Medical College, Zhongshan Hospital, Fudan University, CRR, Infrared spectroscopy correlation table, Society, TTR, Relapse, B-cell lymphoma, Hospital, Pharmaceutical industry, Vaccine, Medical imaging, Management, Safety

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
  • The study of orelabrutinib’s regimen in patients with untreated mantle cell lymphoma (MCL) was selected as an oral presentation.
  • The overall response rate (ORR) was 100%, and the complete response rate (CRR) was 76.2%.
  • This retrospective data suggests that orelabrutinib in combination with rituximab has an encouraging anti-tumor activity in MZL, with a favorable safety profile.

10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH

Retrieved on: 
Wednesday, November 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, HKEX, Macroglobulinemia, PM, Treatment, Refractory, MCL, ASH, Impact, OLR, SSE, Cancer, EST, Society, Relapse, Chronic lymphocytic leukemia, Pharmaceutical industry, Vaccine, Flour, Cyclophosphamide, Patient, Safety

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies from InnoCare’s oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies from InnoCare’s oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
  • A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses
    Session Name: 623.
  • Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
    Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
    Presentation Time: 6:00 PM - 8:00 PM, Dec. 11, 2023 (Monday, EST)
    Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
    Session Name: 623.
  • Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
    Presentation Time: 6:00 PM - 8:00 PM, Dec. 10, 2023 (Sunday, EST)
    Preliminary Safety, Pharmacological, and Efficacy Data from Patients with Relapsed or Refractory B-cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

PURE Bioscience Reports Fiscal First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Technology, Health, General Health, Food, Beverage, Health Technology, Natural Resources, Research, Retail, Software, Science, Momentum, Security (finance), Form 10-K, OTCQB, Poultry, Food safety, OLR, Toxicity, Health, Growth, SDC, Food industry, PURE, Cryptocurrency, COVID-19

PURE Bioscience, Inc. ( OTCQB: PURE ) (PURE, the Company or we), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2022.

Key Points: 
  • PURE Bioscience, Inc. ( OTCQB: PURE ) (PURE, the Company or we), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2022.
  • Net loss for the fiscal first quarter ended October 31, 2022 was $993,000, compared to $796,000 for the fiscal first quarter ended October 31, 2021.
  • Net loss, excluding share-based compensation, for the fiscal first quarter ended October 31, 2022 was $909,000, compared to $606,000 for the fiscal first quarter ended October 31, 2021.
  • Net loss per share was ($0.01) for the fiscal first quarter ended October 31, 2022, compared to ($0.01) for the fiscal first quarter ended October 31, 2021.

PURE Bioscience Reports Fiscal First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, December 15, 2021
Retail, Technology, Other Consumer, Infectious Diseases, Restaurant, Bar, Agriculture, Natural Resources, Supermarket, Other Technology, Biotechnology, Science, Food, Beverage, Consumer, Research, Health, Medical Supplies, Forward-looking statement, U.S. Securities and Exchange Commission, PURE, Consultant, Technology, Lighthouse, Solution, Poultry, FDA, Health Canada, Government, OTCQB, OLR, Company, White Rose Food Division, Produce Marketing Association, Education, Board, Fruit, Toxicity, Growth, Private Securities Litigation Reform Act, Sale, Industry, Director, Adoption, SEC, Chemistry, National Association, Health, Form 10-K, Blind, Association, Marketing, Safety, Transport, Eastman Kodak Co. v. Image Technical Services, Inc., Security (finance), Food safety, National Industrial Training Service of the State of Rio de Janeiro, Software, Program, Public transport, Contract, GSA, SDC, Produce, EPA, Partnership, CRM, Cryptocurrency, Public relations, Pharmaceutical industry, Online shopping, COVID-19

PURE Bioscience, Inc. ( OTCQB: PURE ) (the Company, PURE or we), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2021.

Key Points: 
  • PURE Bioscience, Inc. ( OTCQB: PURE ) (the Company, PURE or we), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2021.
  • Net loss for the fiscal first quarter ended October 31, 2021 was $796,000, compared to $180,000 for the fiscal first quarter ended October 31, 2020.
  • Net loss per share was ($0.01) for the fiscal first quarter ended October 31, 2021, compared to a net loss of ($0.00) for the fiscal first quarter ended October 31, 2020.
  • The increase in gross margin percentage was due to the sale of higher-margin formulations and packaging configurations of our products during the fiscal first quarter ended October 31, 2021, compared to the fiscal first quarter ended October 31, 2020.